KEAP1 and familial pancreatic carcinoma: These observations were further confirmed in 2018 by the same group as BR reduced the Nrf2 protein content in a Keap1-independent manner and decreased the expression of genes related to the multiple drug resistance (MDR) family involved in gemcitabine resistance of pancreatic cancers [90].